Eli Lilly has become an industry leader in GLP-1 therapies, reporting lower-than-expected U.S. sales growth for its diabetes and weight-loss drugs, Mounjaro and Zepbound.
Despite a market slowdown, there remains a large and growing demand for GLP-1 therapies, raising questions about the viability of Eli Lilly as a stock investment.
Novo Nordisk quickly rose to prominence with Ozempic and Wegovy, yet Lilly's Mounjaro and Zepbound have shown greater efficacy, escalating competition in the weight-loss drug sector.
The recent decline in Eli Lilly's stock price comes after it reported $13.5 billion in sales, which fell short of market expectations and contributed to a nearly 7% drop.
Collection
[
|
...
]